Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG chemotherapy + tislelizumab + regorafenib + GM-CSF for neoadjuvant treatment of resectable or borderline resectable pancreatic cancer
ChiCTR2100049343Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, regorafenib, paclitaxel, gemcitabine and sargramostim in pancreatic adenocarcinoma (PDAC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Objective response rate and Major pathological response rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
tislelizumabregorafenibpaclitaxelgemcitabinesargramostim
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2100049343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049343.